2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T60a,The study was designed to obtain a preliminary assessment of the safety and efficacy of SGX945 (dusquetide) for the treatment of aphthous oral and genital ulcers in Behçet's syndrome. This was an open-label pilot study of intravenous dusquetide in patients with Behçet's Syndrome who had at least 2 active oral and/or 1 active genital ulcer(s) at enrolment. Participants were treated twice weekly for 4 weeks and then followed for an additional 4 weeks. Efficacy assessments included number and pain of oral and genital ulcers, overall disease activity assessed using Behçet's Syndrome Current Activity Form and Behçet's Syndrome Activity Scale and health-related quality of life assessed using Behçet's Syndrome Quality of Life Index. Eight participants with oral ulcers were enrolled. Seven of 8 participants reported a perceived benefit including reduction in number, duration, and pain of oral ulcers. Comparison to historical placebo groups demonstrated a reduction in the number of ulcers, time to resolution of ulcers, area under the curve of the ulcer-days, oral pain and baseline quality of life metrics. The treatments were well-tolerated with no treatment-related AEs and no serious or severe adverse events recorded. This small pilot study illustrates the potential efficacy and tolerability of SGX945 in patients with Behçet's syndrome who had ulcers despite being on colchicine maintenance therapy. The results justify further development of SGX945 for the treatment of Behçet's syndrome. Clinicaltrials.gov; NCT06386744.31:T95f,Abstract Objectives The study was designed to obtain a preliminary assessment of the safety and efficacy of SGX945 (dusquetide) for the treatment of aphthous oral and genital ulcers in Behçet’s syndrome. Methods This was an open-label pilot study of intravenous dusquetide in patients with Behçet’s syndrome who had at least two active oral and/or one active genital ulcer(s) at enrolment. Participants were treated twice weekly for 4 weeks and then followed for an additional 4 weeks. Efficacy assessments included number and pain of oral and genital ulcers, overall disease activity assessed using Behçet’s Syndrome Current Activity Form and Behçet’s Syndrome Activity Scale and health-related quality of life assessed using Behçet’s Syndrome Quality of Life Index. Results Eight participants with oral ulcers were enrolled. Seven of eight participants reported a perceived benefit including reduction in number, duration and pain of oral ulcers. Comparison to historical placebo groups demonstrated a reduction in the number of ulcers, time to resolution of ulcers, area under the curve of the ulcer-days, oral pain and baseline quality of life metrics. The treatments were well-tolerated with no treatment-related AEs and no serious or severe adverse events recorded. Conclusion This small pilot study illustrates the potential efficacy and tolerability of SGX945 in patients with Behçet’s syndrome who had ulcers despite being on colchicine maintenance therapy. The results justify further development of SGX945 for the treatment of Behçet’s syndrome. Clinical trial registration Clinicaltrials.gov, http://clinicaltrials.gov, NCT06386744. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Behçet's Disease: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Behçet's Disease (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Beh%C3%A7et's%20Disease\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Behçet's Disease\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Beh%C3%A7et's%20Disease\"}]}}"}}]],["$","$L2f",null,{"title":"Behçet's Disease: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Behçet's Disease with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1080/09273948.2026.2696521","pmid":"42394137","title":"Safety and Efficacy of Adalimumab in the Treatment of Refractory Behçet’s Uveitis: A Prospective Cohort Study","journal_title":"Ocular Immunology and Inflammation","journal_issn":"0927-3948","published_at":"2026-07-02T00:00:00.000Z","url":"https://doi.org/10.1080/09273948.2026.2696521","source_score":4,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-16T13:37:14.451Z","updated_at":"2026-07-16T13:37:14.451Z","tags":[{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"condition","value":"Behçet's Disease","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"condition","value":"Retinal Vasculitis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"condition","value":"Uveitis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"sample_size","value":"n=25","value_numeric":25},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"warning","value":"BCVA is reported in decimal notation (0.14–0.21); the clinical magnitude of this improvement is modest and may not reach the threshold for meaningful visual gain in all patients.","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"warning","value":"Brand tag 'Humira' is used as the reference brand; biosimilar use is not specified in the abstract.","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2696521","tag_type":"warning","value":"Sex distribution of the cohort is not reported in the abstract; the 'mixed' sex tag is assumed based on typical Behçet's disease cohorts.","value_numeric":null}],"summaries":{"what_studied":"This prospective cohort study evaluated adalimumab 40 mg subcutaneously every other week in 25 patients with Behçet's uveitis refractory to conventional immunosuppression, followed for 1 year.","key_result":"Mean BCVA improved from 0.14 to 0.21 (p=0.021); eyes with no anterior chamber reaction rose from 24% to 96% (p<0.001); retinal vasculitis/retinitis/papillitis fell from 92% to 20% (p<0.001); mean corticosteroid dose dropped from 27.2 to 15.2 mg/day (p<0.001). Two patients stopped due to systemic infection; one switched to infliximab for inadequate response.","limitations":"- Very small sample (n=25) limits generalizability and statistical power.\n- No control or comparator arm, so treatment effect cannot be isolated from disease course.\n- One-year follow-up may be insufficient to capture late adverse events or durability of response.","practice_takeaway":"For patients with Behçet's uveitis failing conventional immunosuppression, adalimumab offers meaningful inflammation control and a steroid-sparing effect over 12 months. Monitor closely for systemic infections, which led to discontinuation in 8% of patients in this series."}},{"doi":"10.1080/09273948.2026.2681737","pmid":"42384461","title":"Sex Differences in Uveitis Etiology: A Systematic Review and Meta-Analysis","journal_title":"Ocular Immunology and Inflammation","journal_issn":"0927-3948","published_at":"2026-07-01T00:00:00.000Z","url":"https://doi.org/10.1080/09273948.2026.2681737","source_score":4,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-09T13:36:06.284Z","updated_at":"2026-07-09T13:36:06.284Z","tags":[{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"condition","value":"Ankylosing Spondylitis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"condition","value":"Behçet's Disease","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"condition","value":"Juvenile Idiopathic Arthritis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"condition","value":"Multiple Sclerosis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"condition","value":"Sarcoidosis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"condition","value":"Sympathetic Ophthalmia","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"condition","value":"Syphilitic Uveitis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"condition","value":"Systemic Lupus Erythematosus","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"condition","value":"Uveitis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"condition","value":"Vogt-Koyanagi-Harada Disease","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"sample_size","value":"n=19","value_numeric":19},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"warning","value":"Findings are restricted to specialist uveitis referral cohorts; authors explicitly caution against generalizing RRs as population-level prevalence estimates.","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"warning","value":"Heterogeneity (I²) values are not reported in the abstract; actual degree of between-study variability is unknown from the available text.","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681737","tag_type":"warning","value":"Sample size tag reflects number of included studies (n=19), not total patient count — total patient N is not reported in the abstract.","value_numeric":null}],"summaries":{"what_studied":"This systematic review and meta-analysis (19 studies, 2015–2025; PROSPERO CRD42024531037) examined sex-disaggregated data on known uveitis etiologies across cohort and cross-sectional studies from Asia, Europe, South America, the Middle East, and Africa, using pooled risk ratios (RRs) from random-effects Mantel-Haenszel models.","key_result":"Autoimmune-associated etiologies were more common in females: SLE (RR 2.44), multiple sclerosis (RR 2.39), sarcoidosis (RR 2.02), juvenile idiopathic arthritis (RR 1.86), and Vogt-Koyanagi-Harada disease (RR 1.45). Male-predominant etiologies included syphilitic uveitis (RR 0.41), sympathetic ophthalmia (RR 0.49), Behçet's disease (RR 0.52), and ankylosing spondylitis-associated uveitis (RR 0.55).","limitations":"- Findings derive from specialist uveitis cohorts and may not reflect population-level sex-specific prevalence.\n- Heterogeneity (I²) across included studies is a concern in meta-analyses of this type, and underlying variation by region or referral pattern may confound results.\n- Only 19 studies met inclusion criteria from 2,465 records, limiting the breadth of evidence.","practice_takeaway":"When evaluating uveitis etiology in specialist settings, sex can be a useful diagnostic clue: consider autoimmune causes (SLE, MS, sarcoidosis, JIA, VKH) more strongly in female patients, and HLA-B27-associated or infectious causes (ankylosing spondylitis, syphilis, Behçet's, sympathetic ophthalmia) more strongly in male patients. These patterns should inform—but not narrow—the differential diagnosis."}},{"doi":"10.1080/09273948.2026.2681732","pmid":"42205079","title":"Efficacy of Adalimumab Therapy for Non-Infectious Uveitis in Japanese Patients: Methotrexate Concomitance Across Different Uveitis Etiologies and the Effect of Dose Spacing","journal_title":"Ocular Immunology and Inflammation","journal_issn":"0927-3948","published_at":"2026-05-28T00:00:00.000Z","url":"https://doi.org/10.1080/09273948.2026.2681732","source_score":2,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-06T13:22:51.987Z","updated_at":"2026-06-06T13:22:51.987Z","tags":[{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"condition","value":"Behçet's Disease","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"condition","value":"Non-Infectious Uveitis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"condition","value":"Sclerouveitis","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"condition","value":"Sympathetic Ophthalmia","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"condition","value":"Vogt-Koyanagi-Harada Disease","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"modality","value":"Antimetabolite","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"sample_size","value":"n=83","value_numeric":83},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"warning","value":"All patients were Japanese, which may limit generalizability to other ethnic populations due to differences in uveitis etiology distribution.","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"warning","value":"The dose spacing cohort was small (n=24), so relapse rate and survival estimates carry wide uncertainty.","value_numeric":null},{"paper_doi":"10.1080/09273948.2026.2681732","tag_type":"warning","value":"The etiology-dependent difference in MTX requirements (VKH/sympathetic ophthalmia vs. Behçet's) was described as a trend and was not statistically confirmed; interpret with caution.","value_numeric":null}],"summaries":{"what_studied":"This retrospective study evaluated long-term adalimumab (ADA) efficacy in 83 Japanese patients (160 eyes) with chronic non-infectious uveitis (NIU) or sclerouveitis over ≥6 months, focusing on steroid-sparing effects, etiology-dependent methotrexate (MTX) requirements, and the feasibility of ADA dose spacing.","key_result":"At 12 months, 61.5% (48/78) of patients achieved inactive uveitis; mean oral corticosteroid dose dropped from 13.7 mg/day to 0.9 mg/day (p < 0.0001). Of 24 patients who attempted dose spacing, 14 (58%) relapsed, with a median relapse-free survival of 20.8 months (95% CI 14.5–25.2); most regained disease control by shortening intervals. Late/chronic-stage Vogt-Koyanagi-Harada disease/sympathetic ophthalmia patients trended toward higher MTX requirements than Behçet's disease patients.","limitations":"Retrospective single-center design limits generalizability. The MTX concomitance difference between etiologies was a trend only, not statistically definitive. Dose spacing was attempted in only 24 patients, limiting power for that analysis.","practice_takeaway":"ADA provides meaningful steroid-sparing and inflammation control in NIU, but dose spacing carries a high relapse risk (~58%) and should only be attempted with close monitoring. Etiology—particularly VKH disease/sympathetic ophthalmia vs. Behçet's—may guide decisions about adding MTX."}},{"doi":"10.1002/ppul.71464","pmid":"41521678","title":"Pediatric Behçet's Disease With Pulmonary Embolism, Pulmonary Artery Aneurysm and Multisite Thrombosis","journal_title":"Pediatric Pulmonology","journal_issn":"8755-6863","published_at":"2026-01-12T00:00:00.000Z","url":"https://doi.org/10.1002/ppul.71464","source_score":2,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-16","doi":"10.1002/ppul.71464","days":"7","issn":"8755-6863","rank":"9","field":"Clinical Medicine","score":"2","category":"Respiratory System","categories":["Respiratory System"],"_categories":["Respiratory System"]},"pubmed":{"doi":"10.1002/ppul.71464","title":"Pediatric Behçet's Disease With Pulmonary Embolism, Pulmonary Artery Aneurysm and Multisite Thrombosis.","journal":"Pediatric pulmonology","methods":"","results":"","abstract":"","keywords":["Behcet's syndrome","intracardiac thrombosis","pediatrics","pulmonary artery aneurysm","sinus venous thrombosis"],"pubmed_id":"41521678","conclusions":"","publication_date":"2026-01-12T00:00:00"},"crossref":{"DOI":"10.1002/ppul.71464","URL":"https://doi.org/10.1002/ppul.71464","ISSN":["8755-6863","1099-0496"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.71464","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ppul.71464","content-type":"application/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.71464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"1","score":1,"title":["Pediatric Behçet's Disease With Pulmonary Embolism, Pulmonary Artery Aneurysm and Multisite Thrombosis"],"author":[{"given":"Muhammed","family":"Tekinhatun","sequence":"first","affiliation":[{"name":"Radiology Department Dicle University Hospital Kıtılbıl Turkey"}]},{"given":"Zeynep","family":"Can","sequence":"additional","affiliation":[{"name":"Radiology Department Dicle University Hospital Kıtılbıl Turkey"}]},{"given":"Kadir Han","family":"Alver","sequence":"additional","affiliation":[{"name":"Radiology Department Pamukkale University Hospital Denizli Turkey"}]},{"given":"Ibrahim","family":"Akbudak","sequence":"additional","affiliation":[{"name":"Radiology Department Dicle University Hospital Kıtılbıl Turkey"}]}],"issued":{"date-parts":[[2026,1]]},"member":"311","prefix":"10.1002","source":"Crossref","volume":"61","archive":["Portico"],"created":{"date-time":"2026-01-12T07:20:11Z","timestamp":1768202411000,"date-parts":[[2026,1,12]]},"indexed":{"date-time":"2026-01-12T10:28:34Z","timestamp":1768213714630,"date-parts":[[2026,1,12]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000,"date-parts":[[2026,1,11]]},"delay-in-days":10,"content-version":"vor"},{"URL":"http://doi.wiley.com/10.1002/tdm_license_1.1","start":{"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000,"date-parts":[[2026,1,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1002/ppul.71464"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-08-16"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2026-01-06"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-11"}],"deposited":{"date-time":"2026-01-12T07:20:12Z","timestamp":1768202412000,"date-parts":[[2026,1,12]]},"issn-type":[{"type":"print","value":"8755-6863"},{"type":"electronic","value":"1099-0496"}],"published":{"date-parts":[[2026,1]]},"publisher":"Wiley","reference":[{"DOI":"10.3390/diagnostics13010041","key":"e_1_2_3_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10238-023-01226-7","key":"e_1_2_3_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/ppul.25068","key":"e_1_2_3_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm11051278","key":"e_1_2_3_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/ppul.71202","key":"e_1_2_3_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1002/ppul.71464"],"article-number":"e71464","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2026,1]]},"reference-count":5,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,11]]},"references-count":5,"short-container-title":["Pediatric Pulmonology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1002/ppul.71464","is_oa":true,"title":"Pediatric Behçet's Disease With Pulmonary Embolism, Pulmonary Artery Aneurysm and Multisite Thrombosis","updated":"2026-01-14T02:41:26+00:00","published_date":"2026-01-01","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ppul.71464","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ppul.71464","url_for_landing_page":"https://doi.org/10.1002/ppul.71464"}}},"created_at":"2026-01-21T12:05:26.220Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1002/ppul.71464","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1002/ppul.71464","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1002/ppul.71464","tag_type":"condition","value":"Behçet's Disease","value_numeric":null},{"paper_doi":"10.1002/ppul.71464","tag_type":"condition","value":"Pulmonary Artery Aneurysm","value_numeric":null},{"paper_doi":"10.1002/ppul.71464","tag_type":"condition","value":"Pulmonary Embolism","value_numeric":null},{"paper_doi":"10.1002/ppul.71464","tag_type":"condition","value":"Thrombosis","value_numeric":null},{"paper_doi":"10.1002/ppul.71464","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1002/ppul.71464","tag_type":"warning","value":"Only article metadata was available; no abstract or results were provided for extraction.","value_numeric":null},{"paper_doi":"10.1002/ppul.71464","tag_type":"warning","value":"Study design was inferred from the title and may be inaccurate without full-text review.","value_numeric":null}],"summaries":{"what_studied":"A publication describing pediatric Behçet's disease with pulmonary embolism, pulmonary artery aneurysm, and multisite thrombosis."}},{"doi":"10.1093/rheumatology/keaf682","pmid":"41400947","title":"Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome","journal_title":"Rheumatology","journal_issn":"1462-0324","published_at":"2025-12-16T00:00:00.000Z","url":"https://doi.org/10.1093/rheumatology/keaf682","source_score":18,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-12-29","doi":"10.1093/rheumatology/keaf682","days":"30","issn":"1462-0324","rank":"5","field":"Clinical Medicine","score":"18","category":"Rheumatology","categories":["Rheumatology"],"_categories":["Rheumatology"]},"pubmed":{"doi":"10.1093/rheumatology/keaf682","title":"Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet syndrome.","journal":"Rheumatology (Oxford, England)","methods":"","results":"Eight participants with oral ulcers were enrolled. Seven of 8 participants reported a perceived benefit including reduction in number, duration, and pain of oral ulcers. Comparison to historical placebo groups demonstrated a reduction in the number of ulcers, time to resolution of ulcers, area under the curve of the ulcer-days, oral pain and baseline quality of life metrics. The treatments were well-tolerated with no treatment-related AEs and no serious or severe adverse events recorded.","abstract":"$30","keywords":["Behçet’s Syndrome","dusquetide","genital ulcers","innate immunity","oral ulcers"],"pubmed_id":"41400947","conclusions":"This small pilot study illustrates the potential efficacy and tolerability of SGX945 in patients with Behçet's syndrome who had ulcers despite being on colchicine maintenance therapy. The results justify further development of SGX945 for the treatment of Behçet's syndrome.","publication_date":"2025-12-16T00:00:00"},"crossref":{"DOI":"10.1093/rheumatology/keaf682","URL":"https://doi.org/10.1093/rheumatology/keaf682","ISSN":["1462-0324","1462-0332"],"link":[{"URL":"https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keaf682/65924990/keaf682.pdf","content-type":"application/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keaf682/65924990/keaf682.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome"],"author":[{"given":"Oreola","family":"Donini","sequence":"first","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,"}]},{"given":"Bercemhan","family":"Sulu","sequence":"additional","affiliation":[{"name":"Cerrahpaşa Medical Faculty, Division of Rheumatology, Department of Internal Medicine, Istanbul University – Cerrahpaşa , Istanbul, Türkiye"}]},{"given":"Christopher","family":"Pullion","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,"}]},{"given":"Adam","family":"Rumage","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,"}]},{"given":"Richard","family":"Straube","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,"}]},{"given":"Christopher","family":"Schaber","sequence":"additional","affiliation":[{"name":"Soligenix, Inc. , Princeton, NJ,"}]},{"given":"Gülen","family":"Hatemi","sequence":"additional","affiliation":[{"name":"Cerrahpaşa Medical Faculty, Division of Rheumatology, Department of Internal Medicine, Istanbul University – Cerrahpaşa , Istanbul, Türkiye"}]}],"funder":[{"name":"Soligenix, Inc"}],"issued":{"date-parts":[[2025,12,16]]},"member":"286","prefix":"10.1093","source":"Crossref","volume":null,"created":{"date-time":"2025-12-15T12:29:52Z","timestamp":1765801792000,"date-parts":[[2025,12,15]]},"indexed":{"date-time":"2025-12-28T08:12:53Z","timestamp":1766909573393,"date-parts":[[2025,12,28]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000,"date-parts":[[2025,12,16]]},"delay-in-days":0,"content-version":"am"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaf682/8381546"}},"subtitle":[],"deposited":{"date-time":"2025-12-28T08:11:45Z","timestamp":1766909505000,"date-parts":[[2025,12,28]]},"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"published":{"date-parts":[[2025,12,16]]},"publisher":"Oxford University Press (OUP)","reference":[{"DOI":"10.55563/clinexprheumatol/ra8ize","key":"2025122803113688100_keaf682-B1","year":"2021","issue":null,"author":"Hatemi","volume":"39(Suppl 132)","first-page":"80","unstructured":null,"article-title":"Apremilast for oral ulcers associated with active Behçet’s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial","journal-title":"Clin Exp Rheumatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025122803113688100_keaf682-B2","year":"2020","issue":null,"author":"Hatemi","volume":"38(Suppl 127)","first-page":"3","unstructured":null,"article-title":"One year in review 2020: behçet’s syndrome","journal-title":"Clin Exp Rheumatol","doi-asserted-by":null},{"DOI":"10.1038/nrrheum.2017.208","key":"2025122803113688100_keaf682-B3","year":"2018","issue":null,"author":"Yazici","volume":"14","first-page":"107","unstructured":null,"article-title":"Behçet syndrome: a contemporary view","journal-title":"Nat Rev Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1186/s13075-021-02615-7","key":"2025122803113688100_keaf682-B4","year":"2021","issue":null,"author":"Hammam","volume":"23","first-page":"224","unstructured":null,"article-title":"Epidemiology and treatment of Behcet’s disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions","journal-title":"Arthritis Res Ther","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(23)02629-6","key":"2025122803113688100_keaf682-B5","year":"2024","issue":null,"author":"Emmi","volume":"403","first-page":"1093","unstructured":null,"article-title":"Behçet’s syndrome","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1080/03009742.2021.1885735","key":"2025122803113688100_keaf682-B6","year":"2021","issue":null,"author":"Leccese","volume":"50","first-page":"475","unstructured":null,"article-title":"Clinical phenotypes of Behcet’s syndrome in a large cohort of Italian patients: focus on gender differences","journal-title":"Scand J Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.1002/art.42486","key":"2025122803113688100_keaf682-B7","year":"2023","issue":null,"author":"Le Joncour","volume":"75","first-page":"1628","unstructured":null,"article-title":"Reduction of neutrophil activation by phosphodiesterase 4 blockade in Behçet’s Disease","journal-title":"Arthritis Rheumatol","doi-asserted-by":"crossref"},{"DOI":"10.3389/fmed.2023.1055753","key":"2025122803113688100_keaf682-B8","year":"2023","issue":null,"author":"Shimizu","volume":"10","first-page":"1055753","unstructured":null,"article-title":"Innate immune responses in Behçet disease and relapsing polychondritis","journal-title":"Front Med (Lausanne)","doi-asserted-by":"crossref"},{"DOI":"10.3389/fimmu.2022.852297","key":"2025122803113688100_keaf682-B9","year":"2022","issue":null,"author":"Hirahara","volume":"13","first-page":"852297","unstructured":null,"article-title":"The roles of monocytes and macrophages in Behçet’s Disease with focus on M1 and M2 polarization","journal-title":"Front Immunol","doi-asserted-by":"crossref"},{"DOI":"10.3389/fimmu.2023.1109147","key":"2025122803113688100_keaf682-B10","year":"2023","issue":null,"author":"Li","volume":"14","first-page":"1109147","unstructured":null,"article-title":"Chemokines and chemokine receptors in Behçet’s disease","journal-title":"Front Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1136/annrheumdis-2019-215672","key":"2025122803113688100_keaf682-B11","year":"2020","issue":null,"author":"Hellmich","volume":"79","first-page":"19","unstructured":null,"article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","journal-title":"Ann Rheum Dis","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1816594","key":"2025122803113688100_keaf682-B12","year":"2019","issue":null,"author":"Hatemi","volume":"381","first-page":"1918","unstructured":null,"article-title":"Trial of apremilast for oral ulcers in Behçet’s Syndrome","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jbiotec.2016.03.032","key":"2025122803113688100_keaf682-B13","year":"2016","issue":null,"author":"North","volume":"226","first-page":"24","unstructured":null,"article-title":"A novel approach for emerging and antibiotic resistant infections: innate Defense Regulators as an agnostic therapy","journal-title":"J Biotechnol","doi-asserted-by":"crossref"},{"DOI":"10.1074/jbc.C109.073627","key":"2025122803113688100_keaf682-B14","year":"2009","issue":null,"author":"Yu","volume":"284","first-page":"36007","unstructured":null,"article-title":"Sequestosome-1/p62 is the key intracellular target of innate defense regulator peptide","journal-title":"J Biol Chem","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jbiotec.2016.10.010","key":"2025122803113688100_keaf682-B15","year":"2016","issue":null,"author":"Kudrimoti","volume":"239","first-page":"115","unstructured":null,"article-title":"Randomized, placebo-controlled phase 2a clinical and preclinical data demonstrating a significant and consistent reduction in duration of oral mucositis with a novel innate defense regulator","journal-title":"J Biotechnol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.str.2022.05.003","key":"2025122803113688100_keaf682-B16","year":"2022","issue":null,"author":"Zhang","volume":"30","first-page":"1055","unstructured":null,"article-title":"Dusquetide modulates innate immune response through binding to p62","journal-title":"Structure","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025122803113688100_keaf682-B17","year":"2004","issue":null,"author":"Gilworth","volume":"31","first-page":"931","unstructured":null,"article-title":"Development of the BD-QoL: a quality of life measure specific to Behcet’s disease","journal-title":"J Rheumatol","doi-asserted-by":null},{"DOI":"10.1093/rheumatology/38.8.728","key":"2025122803113688100_keaf682-B18","year":"1999","issue":null,"author":"Bhakta","volume":"38","first-page":"728","unstructured":null,"article-title":"Behcet’s disease: evaluation of a new instrument to measure clinical activity","journal-title":"Rheumatology (Oxford)","doi-asserted-by":"crossref"},{"DOI":null,"key":"2025122803113688100_keaf682-B19","year":"2008","issue":null,"author":"Forbess","volume":"67","first-page":"360","unstructured":null,"article-title":"Behcet’s Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with the Bechcet’s Disease Current Activity Form (BDCAF)","journal-title":"Ann Rheum Dis","doi-asserted-by":null}],"short-title":[],"article-number":"keaf682","content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["Rheumatology"],"reference-count":19,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,16]]},"references-count":19,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1093/rheumatology/keaf682","is_oa":false,"title":"Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome","updated":"2025-12-30T00:50:24+00:00","published_date":"2025-12-15","best_oa_location":null}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"brand","value":"SGX945","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"condition","value":"Behçet's Disease","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"generic","value":"dusquetide","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"sample_size","value":"n=8","value_numeric":8},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"study_design","value":"Open-Label Single-Arm Trial","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"warning","value":"Genital-ulcer efficacy was not detailed despite inclusion criteria allowing genital ulcers.","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"warning","value":"Only abstract-level data were available, with no numerical effect sizes reported.","value_numeric":null},{"paper_doi":"10.1093/rheumatology/keaf682","tag_type":"warning","value":"Study design classification is approximate; this was a single-arm open-label pilot using historical comparators.","value_numeric":null}],"summaries":{"what_studied":"Open-label pilot of intravenous dusquetide (SGX945) given twice weekly for 4 weeks with 4-week follow-up in Behçet’s syndrome patients with active oral and/or genital ulcers; outcomes included ulcer count and pain, disease activity scores, and quality of life.","key_result":"Eight participants with oral ulcers were enrolled; 7/8 reported perceived benefit (fewer, less painful, shorter-duration oral ulcers). Compared with historical placebo groups, there were reductions in ulcer number, time to resolution, ulcer-day AUC, oral pain, and baseline quality-of-life metrics; no treatment-related AEs and no serious or severe AEs were recorded.","limitations":"Very small single-arm, open-label study (n=8) with comparisons to historical placebo, limiting causal inference. Short treatment and follow-up (4+4 weeks), and genital-ulcer outcomes were not specifically quantified.","practice_takeaway":"Dusquetide (SGX945) showed perceived symptom improvement and was well tolerated in a small cohort of Behçet’s patients with ulcers despite colchicine, but evidence is preliminary; reserve judgment pending randomized trials."}}],"initialOffset":5,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Behçet's Disease"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Behçet's Disease"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Behçet's Disease"}}}]]

Papers